Vitamin D Improves Osteoporosis in Postmenopausal Women With Denosumab Failure
Abstract
Denosumab is a monoclonal antibody against RANKL ligand, which is used as an alternative treatment for osteoporosis in patients who have a poor response to first-line antiresorptive therapy. However, discontinuation of denosumab produces a rapid increase in bone turnover, bone loss and potentially increased risk of multiple vertebral fractures.
Conditions: Hypovitaminosis D, Osteoporosis, Postmenopausal, Menopause.
Primary outcome: Number of participants with hip T-score improvement at 12 months; Number of participants with lumbar spine T-score improvement at 12 months; Number of participants with osteoporosis of the hip at 12 months; Number of participants with osteoporosis of the lumbar spine at 12 months; Number of participants with osteopenia on the hip at 12 months; Number of participants with osteopenia of the lumbar spine at 12 months; Number of participants with normal hip T-score at 12 months; Number of participants with normal lumbar spine T-score at 12 months; Number of participants with improvement in serum levels of vitamin D at 12 months; Number of participants with clinical remission of hypovitaminosis D at 12 months.
Enrollment: 55 participants.
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 55 participants or records.
Read the paper
Related studies
- Effectiveness of Bisphosphonates and Denosumab on Risk of Vertebral Fractures in Prostate Cancer Patients Under Androgen Deprivation Therapies: A Real-World Prospective Study
- Osteoporosis-related fractures after spinal cord injury: a retrospective study from Brazil
- Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men
- Lack of Association between Vitamin D Insufficiency and Cardiovascular or Fracture Risk: A UK Biobank Study
- Muscle strength and body composition are clinical indicators of osteoporosis
- Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.